Loading stock data…
$2.14-0.11 (-4.89%)
Aclarion, Inc.
Aclarion, Inc. in the Healthcare sector is trading at $2.14 with a market capitalization of $7M. Wall Street consensus targets $7.62 (2 analysts), implying a +256.3% move over the next 12 months. The stock is currently near its 52-week low of $1.95, remaining 30.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25,208↑ | $21,140↑ | $18,479↓ | $18,942↓ | $19,319 |
| Gross Profit | $8,297↑ | $3,750↑ | $1,791↓ | $4,386↓ | $5,140 |
| Operating Income | -$2.90M↑ | -$2.99M↓ | -$1.99M↓ | -$1.83M↓ | -$1.74M |
| Net Income | -$2.75M↑ | -$2.85M↓ | -$1.89M↓ | -$1.71M↓ | -$1.60M |
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, whic...